Cambridge, United Kingdom

Anne Cochi



 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Anne Cochi

Introduction

Anne Cochi is a notable inventor based in Great Britain. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific enzyme activities. Her work focuses on innovative solutions for treating proliferative disorders, including cancer.

Latest Patents

Anne Cochi holds a patent titled "Preparation And Uses Of Pyrimidinone Derivatives." This invention relates to compounds that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The compounds are defined by a specific formula, which includes various components such as X, R1, R2, and n. The invention also encompasses processes for preparing these compounds, pharmaceutical compositions that include them, and their applications in treating diseases where Cdc7 kinase activity is implicated.

Career Highlights

Throughout her career, Anne Cochi has focused on the intersection of chemistry and medicine. Her research has led to advancements in understanding how certain compounds can inhibit critical processes in cell division. This work is essential for developing new therapeutic strategies for cancer and other related conditions.

Collaborations

Anne has collaborated with Emma L Carswell, contributing to the development of her innovative compounds. Their partnership has been instrumental in advancing research in the field of kinase inhibitors.

Conclusion

Anne Cochi's contributions to the field of pharmaceuticals highlight her innovative spirit and dedication to improving treatment options for serious health conditions. Her work continues to inspire future research and development in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…